Healthcare / Medical Instruments & SuppliesNasdaqCM
$21.96
+0.04 (+0.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-253084.00 · quality 20.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$201M
P/E
366.0x
↑EV/EBITDA
21.4x
↑ROE
-632.5%
↓Gross Margin
92.7%
↑Debt/Equity
8.12
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+37.1%
FCF CAGR
—
FCF margin
2.1%
FCF / Net income
-0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $103.1M · net income $-37.6M · FCF $2.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $103.1M | $103.1M | $86.7M | $65.0M | $45.8M | $24.1M | $15.6M | $11.8M | $5.8M | $6.3M | $5.5M | $3.4M | $2.6M | $1.7M | $1.2M | $2.2M | $910420.00 |
| Net Income | $-37.6M | $-37.6M | $-9.7M | $-4.3M | $-7.9M | $-7.9M | $-4.4M | $-2.8M | $-600574.00 | $331309.00 | $-415747.00 | $-1.3M | $-2.3M | $-4.1M | $-1.8M | $-12.7M | $-6.6M |
| EBITDA | $10.3M | $10.3M | $6.1M | $-289093.00 | $-11.6M | $-6.8M | $-4.7M | $-2.6M | $-417970.00 | $201092.00 | $-211250.00 | $-904950.00 | — | — | — | $-4.5M | $-2.0M |
| EPS | -4.36 | -4.36 | -1.14 | -0.52 | -1.00 | -1.08 | -0.76 | -1.32 | 0.00 | 0.00 | -1.00 | — | — | — | — | — | — |
| Gross Margin | 92.7% | 92.7% | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% | 89.7% | 91.3% | 87.2% | 82.9% | 73.5% | 69.5% | 54.1% | 32.0% | 63.8% | 40.9% |
| Operating Margin | 8.9% | 8.9% | 1.4% | -11.8% | -26.7% | -30.6% | -32.3% | -23.3% | -8.6% | 1.9% | -4.9% | -28.6% | — | — | — | -226.9% | -271.9% |
| Net Margin | -36.4% | -36.4% | -11.2% | -6.6% | -17.3% | -32.8% | -28.5% | -23.9% | -10.3% | 5.3% | -7.5% | -39.8% | -86.5% | -240.3% | -157.2% | -576.6% | -729.5% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 8.12 | 8.12 | 0.82 | 0.26 | 0.02 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 2.28 | 2.28 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $2.1M | $2.1M | $-253084.00 | $-3.5M | $-6.3M | $-5.0M | $-4.6M | $-2.4M | $268660.00 | $-183757.00 | $406216.00 | $-1.2M | $-1.7M | $-1.9M | — | — | — |
| Returns | |||||||||||||||||
| ROE | -632.5% | -632.5% | -24.5% | -9.6% | -19.0% | -25.9% | -72.3% | -42.5% | -102.3% | 323.1% | 98.3% | 105.4% | 276.0% | 168.0% | 48.5% | 330.1% | -1190.7% |
| Valuation | |||||||||||||||||
| P/E | 366.00 | 366.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 21.43 | 21.43 | 49.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 31.89 | 31.89 | 7.21 | 7.40 | 7.70 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 19.0% | 19.0% | 33.4% | 41.8% | — | 54.9% | 32.5% | 101.6% | -7.4% | 14.5% | 63.3% | 28.1% | 52.5% | 47.1% | -46.9% | 142.7% | — |
| EPS Growth | -282.5% | -282.5% | -119.2% | 48.0% | — | -42.1% | 42.4% | — | — | 100.0% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.14 → -4.36
Residual
-24.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.